FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:50-51 July 3, 1997 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Roberts, W. M.

To the Editor: Roberts and his colleagues (Jan. 30 issue)¹ do not emphasize that childhood acute lymphoblastic leukemia (ALL) is a heterogeneous disease with different rates of elimination of blast cells. The kinetics of the decrease in the minimal residual disease and the level of minimal residual disease that is compatible with a cure may differ among the leukemias and among the cytogenetic or immunophenotypic subtypes of childhood ALL.

For example, of six patients with a first complete remission of t(1;19)-positive ALL, five had molecular remissions within 3 months, and one had minimal residual disease after 84 months of complete . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.